Approved

Palatin Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

AMAG Pharmaceuticals Completes Divestment of Women’s Health Assets

Lead Product(s): Bremelanotide

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: AMAG Pharmaceuticals

Deal Size: $16.3 million Upfront Cash: $12.0 million

Deal Type: Divestment July 27, 2020

Details:

Under the terms of the termination agreement, all of AMAG’s rights and obligations to develop and commercialize Vyleesi under the license agreement will terminate, and full ownership of Vyleesi will transfer back to Palatin.

Nurx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

TherapeuticsMD and Nurx Expand Access to ANNOVERA®

Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Annovera

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: TherapeuticMD

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 15, 2020

Details:

The agreement is aimed at expanding access to ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), a first of its kind annual birth control ring. ANNOVERA is the first FDA-approved long-lasting birth control method that does not require a medical procedure.

Evofem Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Evofem Biosciences Announces Pivotal Phase 3 AMPOWER Study Results For Phexxi™ in Contraception

Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Phexxi

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

The final data analysis demonstrated a cumulative pregnancy rate of 13.7% over seven cycles of use in Phexxi group.

Mithra Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Mithra to Commercialize Myring In France, Poland And UK

Lead Product(s): Etonogestrel,Ethinyl Estradiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Myring

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Zentiva, k.s.

Deal Size: $2.2 million Upfront Cash: Undisclosed

Deal Type: Agreement July 06, 2020

Details:

Mithra grants license to Zentiva for commercialization of its vaginal contraceptive ring in three key European markets.

Intas Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Naari Completes Acquisition of ANDAs from Intas Pharmaceuticals

Lead Product(s): Undisclosed

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Undisclosed

Partner/Sponsor/Collaborator: Naari

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition June 10, 2020

Details:

The portfolio acquired comprises eight U.S. FDA approved ANDAs and two products pending approval. It includes generic products in female hormones which will be manufactured at Naari’s dedicated female hormone facility in India and commercialized over the next 24 months.

Evofem Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

U.S. FDA Approves Evofem Biosciences' Phexxi™ (Lactic acid, Citric acid and Potassium bitartrate), the First and Only Non-Hormonal Prescri...

Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 22, 2020

Details:

Data demonstrate high efficacy rates of more than 93% when Phexxi is used as directed, also underscore the sexual satisfaction and lubricating factors experienced by women in the AMPOWER trial.

Duchesnay

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Duchesnay Usa & Plushcare Announce a New Partnership to Facilitate Access to Healthcare for Menopausal Women Through Telemedicine

Lead Product(s): Ospemifene

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Plushcare

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 19, 2020

Details:

The aim of this partnership is to provide Duchesnay USA's Osphena® (ospemifene) to women suffering from vaginal symptoms related to menopause, with the possibility of having this conversation with a healthcare provider in the comfort and privacy of their own home.

Ferring Pharmaceuticals Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Ferring Pharmaceuticals Welcomes Swissmedic Approval of Carbetocin Ferring for the Prevention of Postpartum Haemorrhage in All Births

Lead Product(s): Carbetocin

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

Carbetocin Ferring is the first medicine approved under the new Swissmedic and Marketing Authorisation for Global Health Products (MAGHP) procedure, which aims to build capacity and speed up access to essential medicines in low- and middle-income countries.

Mithra Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Mithra Pharmaceuticals and Gynial Sign Commercialization Agreement for Myring™ in Switzerland

Lead Product(s): Etonogestrel,Ethinyl Estradiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Gynial

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 05, 2020

Details:

Under the terms of this agreement, Gynial will distribute Myring™ in Switzerland, where the Swiss contraceptive rings market is worth EUR 8 million per year.

Afaxys Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

TherapeuticsMD and Afaxys Enter Into Agreement

Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: TherapeuticsMD

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 13, 2020

Details:

The arrangement combines Afaxys' unique capabilities serving the United States public health contraception market with TherapeuticsMD’s commitment to supply ANNOVERA to the U.S public health system.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Palatin Technologies

AMAG Pharmaceuticals Completes Divestment of Women’s Health Assets

Nurx

TherapeuticsMD and Nurx Expand Access to ANNOVERA®

Evofem Biosciences

Evofem Biosciences Announces Pivotal Phase 3 AMPOWER Study Results For Phexxi™ in Contraception

Mithra Pharmaceuticals

Mithra to Commercialize Myring In France, Poland And UK

Intas Pharmaceuticals

Naari Completes Acquisition of ANDAs from Intas Pharmaceuticals

Evofem Biosciences

U.S. FDA Approves Evofem Biosciences' Phexxi™ (Lactic acid, Citric acid and Potassium bitartrate), the First and Only Non-Hormonal Prescri...

Duchesnay

Duchesnay Usa & Plushcare Announce a New Partnership to Facilitate Access to Healthcare for Menopausal Women Through Telemedicine

Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Welcomes Swissmedic Approval of Carbetocin Ferring for the Prevention of Postpartum Haemorrhage in All Births

Mithra Pharmaceuticals

Mithra Pharmaceuticals and Gynial Sign Commercialization Agreement for Myring™ in Switzerland

Afaxys Pharma

TherapeuticsMD and Afaxys Enter Into Agreement